NCT04076059 2026-04-17
China ARCHES
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
22 trialsNCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03767244 2026-04-13
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108208 2026-04-13
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT04191096 2026-03-20
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05477823 2026-03-20
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05884398 2026-03-12
LIBERTAS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT02296229 2026-02-25
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT04126070 2026-01-22
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03456843 2026-01-21
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Yale University
Phase 2 Active not recruiting
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT02454543 2026-01-12
g-RAMPP
Martini-Klinik am UKE GmbH
Phase NA Active not recruiting
NCT05746806 2025-12-31
HypoFocal SRT
Insel Gruppe AG, University Hospital Bern
Phase NA Active not recruiting
NCT03541850 2025-11-06
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05628363 2025-11-05
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Washington University School of Medicine
Phase NA Active not recruiting
NCT05100472 2025-11-04
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04743934 2025-05-04
RAD 2003
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT04624828 2025-04-24
IOSCAR
Istituto Clinico Humanitas
Phase NA Active not recruiting